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ABSTRACT 
We have recently developed a new method to detect and characterize single 
base substitutions in transcribed genes which is based on the ability of RNAse A 
to recognize and cleave single base mismatches in RNA:RNA heteroduplexes. The 
RNAse A misrnatch cleavage assay was applied to screen human colon carcinoma cell 
lines and primary tumors for the presence of mutant e-X-ras oncogenes. We 
have determined that the mutant e-X-ras allele is overexpressed and amplified 
relative to the normal in the SX-CO-l human colon carcinoma cell lineo The 
oncogene mutation has been characterized by this method as a glycine to valine 
substitution at codon 12 of the e-X-ras gene. This result was confirmed by 
cloning and sequencing. We have previously reported that about 40% of primary 
human colon tumors contain e-X-ras genes mutant at codon 12 (Forres ter et al, 
Nature 327: 298, 1987). We report here the characterization by molecular cloning 
and sequencing of the mutation in the e-X-ras oneogene from two of these tumors 
(tumors 3 and 28). We also describe the histopathologieal eharaeterization of 
these two tumors and demonstrate, by Southern blot hybridization of NIH3T3 
transformants, the simultaneous presenee of mutant e-X-ras and N-ras oncogenes 
in villous adenoma 28. Our results provide evidence for the frequent assoeiation 
of ras somatie mutational aetivation in the early stages of tumor development in 
this common type of human eaneer. 
INTRODUCTION 
Proto-oncogenes are a class of cellular genes which possess oncogenic 
potential. Genetic alterations of a diverse nature can lead to the activation of 
the malignant potential of cellular proto-oncogenes. The activated proto­
oncogenes are known as oncogenes. Increasing evidence supports the concept that 
combinations of multiple genetic abnormalities, sorne of which result in the 
activation of cellular oncogenes, are intrinsic to the tumorigenesis process (see 
ref 1 for a review). 
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Tbree characterized members of the ras gene family (c-H-ras, coK-ras, and 
N-ras) acquire direct oncogenic activity in certain cultured cells by point 
mutations in their coding regions (reviewed in 2). Tbese mutations result in the 
synthesis of proteins containing single amino acid substitutions at preferential 
locations: codons 12, 13, and 61. Mutant ras oncogenes are frequently and 
reproducibly involved in the generation of defined tumors iri some animal model 
systems (see ref 3 for a recent review). In addition to these qualitative 
changes, other genetic alterations resulting in increased gene expression are 
associated with the manifestation of the ras gene malignant potential (reviewed 
in 4). Tbese findings support the hypothesis that ras oncogenes contribute in a 
dominant but dose-dependent manner to the multistage process of tumor development 
and progression. 
Although ras oncogenes have been identlfied in a significant proportion of 
human tumors, their incidence and distribution according to tumor type have not 
been accurately determined. A reason for the lack of accurate information on the 
incidence of ras oncogenes in primary human tumors lies in the technical 
difficulties intrinsic to the methods used for the detection of single base 
substitutions in genes from organisms with large genomes. 
We have previously developed a novel method to detect and characterize 
single base substitutions in transcribed genes (5) whic,h offers several 
advantages over other methods currently available,. Tbe method is based on the 
ability of RNAse A to recognize and cleave single base mismatches in RNA:RNA 
duplexes. A homogeneously labeled antisense RNA probe is hybridized to total 
cellular RNA. Tbe RNA:RNA duplexes are then digested with RNAse A and the 
resulting RNA fragments are analyzed on a denaturing polyacrylamide gel. Because 
the size of these fragments is dependent on the position of the mismatch in the 
RNA duplex, the method permits for the localization of the point mutations in the 
gene transcripts. A schematic representation of the method is outlined in Figure 
l. We have applied this method to the analysis of the involvement of ras 
mutational activation in human cancer. We describe here our findings on the 
incidence of mutant coK-ras oncogenes in human colo-rectal tumors. 
EXPERIMENTAL PROCEDURES 
Cell Cultures and Transfection Experiments 
Tbe origins of the human tumor cell lines SK-CO-l, SW4S0, PR37l, and 
normal foreskin fibroblasts (HNF) have been previously described (5). Human cells 
were grown in Dulbecco's modified essential medium (DMEM) containing 10% fetal 
calf serum. NIH3T3 mouse fibroblasts were grown in DMEM containing 10% bovine 
calf serUm. Transfection assays were performed using the calcium phosphate 
coprecipitation method (6,7) as previously described (S). Foci of morphologically 
transformed NIH3T3 cells were scored 3 weeks after transfection and individual 
transformants were isolated and grown in mass culture for further analysis. 
RNA and DNA Extractions and Southern Blot Hybridizations 
Tbe sources of tumor tissue and diagnostic characterization have been 
previously described (9). RNA was prepared from cultured cells or from frozen 
tumors by sequential guanidine HC1-ethanol and phenol extractions as described 
(10). Tbe quality of the RNA was examined by formaldehyde-agarose gels and 
staining with ethidium bromide. Only samples of tumor RNA showing the presence of 
ribosomal 2SS and lSS RNA stained bands at approximate ratios of 2:1 were used 
for the RNAse A mismatch cleavage method. High molecular weight DNA was prepared 
from frozen tumors and cultured cells as described (S,ll). Southern blot 
experiments were performed by transfer of restrict~~n endonuclease-digested DNA 
to nitrocellulose membranes and hybridization with -P-labeled coK-ras or N-ras 
specific DNÁ probes as described (10). 
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BESULTS ANO DISCUSSION 
Characterization and Expression of Mutant coK-ras Genes in Human Colon Carcinoma 
Cell Lines 
Using the RNAse A mismatch cleavage method (Figure 1), we have previously 
described the presence of single point mutations at codon 12 of the coK-ras gene 
of SK-LU-l lung carcinoma and SK-CO-l colon carcinoma human tumor-derived cell 
lines, and we predicted that these mutations resided at the second position of 
the triplet (S). We have now characterized the mutation of SK-CO-l tumor cells 
(Figure 2), using an antisense RNA probe corresponding to the first coding exon 
of the coK-ras oncogene from SW480 colon carcinoma cells, which contains a G-T 
transversion at the second position of codon 12 resulting in the replacement by 
valine of the glycine encoded by the normal triplet (GGT) (17). 
When total cellular RNA from SW480 and SK-CO-l was hybridized to the 
antisense RNA probe corresponding to the first normal exon of the coK-ras gene 
(anti GLY) , digestion with RNAse A yielded, together with a 114 nucleotides 
protected band, RNA fragments of 67 and 46 nucleotides diagnostic of the presence 
of a point mutation at codon 12 of the coK-ras transcript. These bands were also 
present after hybridization and digestion of RNA from PR37l lung carcinoma cell 
line, which contains a coK-ras gene with a cysteine mutation (TGT) at codon 12 
(11). However, RNA from normal fibroblasts only yielded a major 114 nucleotides 
band representing the full-length protected RNA fragmento 
When hybridized to the antivaline mutant probe (anti VAL), RNA from normal 
fibroblasts was cleaved by the enzyme, yielding RNA fragments of 88 and 67 
nucleotides diagnostic of a mismatch at codon 12. The difference in size of one 
of the mismatch-specific RNA fragments (46 or 88 nucleotides with the anti GLY or 
anti VAL probes, respectively) is due to the presence of S' untranslated exon 
sequences in the valine mutant probe. The coK-ras transcripts present in PR37l 
RNA were cleaved to almost completion by the enzyme generating the diagnostic 88 
and 67 nucleotides subbands. However, these bands were absent when RNA from SW480 
cells was hybridized and digested under the same conditions, and only a major 
band of 154 nucleotides, corresponding to the fu1l-length protected RNA fragment, 
was apparent. These resu1ts indicate the absence of normal CoK-ras transcripts in 
SW480 colon carcinoma cells, in agreement with the results obtained by cDNA 
cloning and sequencing (17). A minor band of about 114 nucleotides corresponding 
to the unsp1iced coK-ras transcript and other faint nonspecific bands were a1so 
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FIGURE 1. Scheroatic Representation of the RNAse A Mismatch Cle.vage Method 
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apparent. SK-CO-l RNA was mostly protected from the nuclease attack although a 
mInor proportion of the hybrids were also cleaved, generating the 88 and 67 
nucleotides codon 12 mismatch-specific subbands. 
These results indicate that the normal coK-ras al le le is present in SK-CO-l 
cells. These results also predIct that the mutation in the coK-ras gene of the 
SK-CO-l cell line is the same valine mutation as that present in the SW480 cell 
lineo This prediction was confirmed by clonlng and sequencing the first coding 
exon of the coK-ras gene from SK-CO-l cells (Figure 3), demonstrating the 
applicability of the RNAse A cleavage method to characterize single point 
mutatIons in transcribed genes. 
Comparlson of the extent of cleavage by RNAse A of heteroduplexes generated 
by hybridization with the normal or mutant RNA probes indicated that, similar to 
the situatIon in Calu-l and PR37l lung carcinoma cell lines (5), the mutant 
coK-ras allele is overexpressed (2 to 3 fold) relative to the normal allele in 
SK-CO-l colon carcinoma cells (Figure 2). Analysis of the coK-ras alleles using 
restriction endonuclease polymorphisms in the coK-ras locus (5), revealed that 
the mutant allele is amplified 2-4 fold relative to its normal counterpart in 
SK-CO-l tumor cells (data not shown). 
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FIGURE 2. RNAse A Mismatch Cleavage Analysis of coK-ras Transcripts from 
SK-CO-l Colon Carcinoma Cell Line. 
Thirty micrograms of ~otal cellular RNA from the cell lines indicated at the 
top were hybridized with 3 P labeled antisense RNA (105 cpm) dIrected by pAK1Ngly 
and pAKlMval vectors as described in Experimental . Procedures. RNA hybrids were 
digested with RNAse A for 30 and 90 minutes (shown from left to right) at 300 C 
and analyzed by denaturing polyacrylamide electrophoresis and auto­
radiography. HNF: human normal foreskin fibroblasts. P: undigested RNA probes. 
Numbers at the left indicate the position and (in nucleotides) of OX1794 DNA 
HaeIII restriction fragments used as molecular weight markers (M). Arrows at the 
right indicate the size of the RNA fragments generated by RNAse A digestion of 
the hybridized transcripts. 
Gene Cloning and Seguencing 
DNA fragments containing the first coding exon of the coK-ras gene from 
tumors 3 and 28 and from the tumor cell line SK-CO-l were isolated by 
constructing partial genomic libraries of HíndIII digested DNA cloned into the 
lambda 47.1 phage vector and screening with c-K-ras-specific DNA probes as 
described (11). The lSKb HíndIII fragment of the coK-ras gene from tumor 3 was 
iso1ated from DNA of a NIH3T3 primary transformant, whi1e the gene fragments from 
tumor 28 and cell line SK-CO-1 were isolated direct1y from the human tumor cell 
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DNA. Three recombinant phages were isolated from the NIH3T3 transformant library, 
and one recombinant clone was isolated from each of the human DNA libraries. The 
280 bp Sau3A-Pstl fragments containing sequences of the first coding exon of the 
c-K-ras gene from tumors 3 and 28 and the 1.4Kb Stul-Xbal fragment containing the 
first coding exon of the gene from the SK-CO-l cell line were subcloned into 
the BamHI-Pstl and the SmaI-Xbal sites of the pGEM-4 vector (Promega Biotec.), 
respectively. The first coding exons of the c-K-ras gene from these human tumor 
cells were sequenced by the Maxam-Gilbert chemical method as described (11). 
Plasmid Constructions and in vitro Transcriptions 
A plasmid directing the synthesis of antisense RNA containing a valine 
mutation at codon 12 of the c-K-ras gene (pAKlMval) was constructed by subcloning 
the 154 bp Sau3A-Pstl fragment of p3035 (obtained from Oncor) into the BamHI-Pstl 
sites of the pSP65 vector (Promega Biotec.). p3035 is a full length cDNA clone of 
the c-K-ras oncogene from the SW480 colon carcinoma cell line (12). Construction 
of plasmids pAKlNgly and pAKlMser has been previously described (5,9). The 200 bp 
Sau3A-Hindlll fragment corresponding to the first coding exon of the human N-ras 
gene (13) was similarly cloned into the BamHI-Hindlll sites of pGEM4, 
generating pANlNgly. The N-ras fragment was subcloned from pNR9.2, a plasmid 
containing the 5' 9.2Kb EcoRI fragment of the human N-ras gene cloned into the 
EcoRI site of pAT153 (13). Plasmid pKRSm2.6 contains the 2.6kb EcoRI-Smal frag­
ment corresponding to the 5' distal region of the c-K-ras gene (5). 
Radioactive RNA probes were synthesized with the SP6 Polymerase in vitro 
transcription system (14) as previously described (5). One microgram of the 
appropriate plasmid was linearized with Hindlll and incubated with SP6 RNA 
Polymerase (Promega B~~tec.) in the presence of 0.5mM each of ATP, GTP, and UTP 
and l2uM of CTP and P-CTP (Amersham, 10mCi/ml, >400Ci/mmol) for 60 minutes at 
40oC. After removal of unincorporated nucleotides by ethanol precipitation, the 
RNA probes were purified by denaturing polyacrylamide gel electrophoresis (15). 
We found that this step eliminated some unspecific background bands originating 
from the presence of foldback products generated during the in vitro 
transcription reaction (14,16). Gel slices containing the synthesized RNA were 
transferred to sterile microfuge tubes and shaken at 37 0 C for three hours in 
375ul of 2M NH40Ac and 0.1% SDS. The samples were centrifuged and the super­
natants were precipitated with ethanol in the presence of carrier tRNA. The 
pellets were washed with ethanol, lyophilyzed and dissolved in hybridization 
buffer (5). The RNA probes were stored at -70oC and used within 4 days. 
Hybridizations and RNAse A Digestions 
Total cellular RNA was hybridized to the appropriate antisense 
32-P-labeled RNA probe (105 cpm) for 12-18 hours at 500 C and digested with RNAse 
A (Type lIlA, Sigma or PL Biochemicals) essentially as previously described 
(5). For RNAse A treatment, the enzyme concentration, length of digestion and 
incubation temperature were adjusted depending on the nature of the mismatches 
present in the RNA hybrids. Generally, digestions using RNAse A at concentrations 
of 20-40 ug/ml at 25-30oC for 30-60 minutes were sufficient. RNAse treatment was 
terminatedby digestion with Proteinase K (Sigma) inthe presence of SDS and the 
protein was removed by phenol extractión. The RNA was e thano1 precipitated, and 
analyzed by denaturing polyacrylamide gel electrophoresis as described (5). 
Detection of Mutant c-K-ras Gene"s in Human Primary Colon Tumors 
We have screened a large panel of primary human colon tumors for the 
presence of c-K-ras genes with mutations in its first coding exon using the RNAse 
A mismatch cleavage method. Total cellular RNA prepared from frozen tumors was 
hybridized to an antisense RNA probe. This probe spans most of the c-K-ras first 
coding exon, from the Sau3A site to the 5' splice acceptor site and approximately 
180 additional nucleotides of upstream intron sequences (5) an encodes either a 
glycine or serine at position 12 (5,9). The hybrids were digested with RNAse A 
and analyzed by denaturing polyacrylamide gel electrophoresis. 
Hybridization of this antisense RNA probe to mature normal c-K-ras mRNA 
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TABLE l. 
Incidence of coK-ras Oncogenes in Primary Human Colon Tumors 
a: Type of primary colon tumor. b: Position of the mutated nucleotide 
in the normal triplet (GGT) at position 12 of the coK-ras gene. N: A, T, or C. 
c: Number and total percentage of mutations detected at either the first of 
second positioD of codon 12 by the RNAse A mismatch cleavage method. d: number 
and total percentage of coK-ras oncogenes as determined by the NIH3T3 
transfection assay. e: Grade of invasiveness of the tumors following Duke's 
classification (18). The numbers are positive tumors/total tumors analyzed in 
each group. O, non-invasive tumor. f: Metastases present (+) or absent (-) at 
time of surgery. The numbers are positive cases/total cases analyzed. 
e f 
a b e d GRAPE METASTASES 
TYPE NUMBER MUTATlON RNAseA NIH:ST3 O A B e 1) + 
APENOCA. 68 CODON 12 27/68
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7/35 
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NGT 5 3 1 3 o 1 O 4 1 
GNT 2 O O 1 1 O o 2 o 
APENCJoIAT. 
POLYPS 
6 1/6
16% 
NO NA NA NA NA NA 1/6 NA 
followed by digestion with RNAse A generates a protected RNA duplex of 114 bp. 
When the probe is annealed to coK-ras transcripts containing single base 
substitutions at codon 12, digestion with the enzyme generates fragments of 67 
and 46 nucleotides indicating the presence of a mutant coK-ras gene at this 
position (see Figure 2). The results obtained in our studies with a series of 68 
primary colon turnors has recently been reported (9) and are summarized in 
Table l. 
Fragments of the coK-ras genes from two turnors which scored positive in our 
assay (turnors 3 and 28) were molecularly cloned and their first coding exons 
sequenced. The result of these experiments confirmed the presence of point 
mutations at codon 12 of the coK-ras gene in these t~ors. The mutations were 
characterized as cysteine (TGT) and serine (AGT) substitutions, respectively 
(Figure 3). The activation of the transforming potential of the coK-ras gene by 
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-FIGURE 3. Seguence Analysis of the Mutant CoK-ras Genes from Colon Tumors 3 
and 28 and from Colon Carcinoma Cell Line SK-CQ-l. 
Autoradiography of sequencing ladders of the coK-ras first coding exon from 
colon turnors 28 (2), 3(3) and colon carcinoma cell line SK-CO-l (4). Parallel 
sequence analysis of the first coding exon of PR310 lung carcinoma cell line, 
which contains a c-K-ras gene normal at position 12 (11) is also shown (1). The 
nucleotide sequence of codon 12 is indicated at the left. 
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these point mutations was demonstrated by transfection of chimeric 
c-K-raslc-H-ras genes into NIH3T3 cells. The chimeras contained the first coding 
exons of the coK-ras gene from tumors 3 or 28 (data not shown). These results 
demonstrate the validity of the RNAse A mismatch cleavage method for the 
diagnostic detection of ras genes containing single base point mutations in 
primary tumors. 
cOK-ras Mutational Frequency in Primary Human Colon Turnors 
Our results indicate that about 40% (27 of 68) of primary colon tumor s 
contain coK-ras genes mutant at position 12 (9). Mutant coK-ras genes were not 
detected in RNA prepared from normal colonic tissue from the same patlents and no 
mutations were found at other positions within the first coding exon. Thus, the 
location of somatic point mutations in the coK-ras gene ls speciflc for spots 
that actlvate lts transforming potentlal (i.e. codon 12). Because the RNAse A 
mismatch cleavage method is not dependent on the posltlon of the mutation in the 
gene transcript covered by the RNA probe, this result argues against the 
hypothesis that mutations in ras genes are a secondary consequence of the higher 
mutation rate of turnor cells (19). If this were the case, random mutations in 
other regions of the gene should have been detected. Instead, our results 
strongly suppórt the concept that ras somatic mutational activation ls directly 
associated wlth the tumorigenesis process. 
The RNAse A mismatch cleavage method ls more sensitive in detecting coK-ras 
oncogenes in prlmary tumors than the NIH3T3 focus formation assay. Parallel 
experiments showed that DNA from only 20% of the turnors was able to induce the 
morphological transformation of NIH3T3 cells. Unspecific degradation of turnor DNA 
(due to necrosis or insufficient preservation of frozen tumor tissue) might lead 
to a decrease in its transfection efficiency to levels below detection in the 
focus assay. lt ls noteworthy that we were able to detect mutant coK-ras 
oncogenes with our method in frozen tumors which included contaminating normal 
stromal tissue, without prior selection for carcinoma tissue through histo­
pathological analysis. We estimate that our method can detect the presence of 
coK-ras oncogenes in solid tumors containing a minimum of 5-10% mutant 
transcripts in the total tumor RNA population. 
No significant differences were observed between the mutation frequency 
at codon 12 of the coK-ras gene and the degree of differentiation or stage of 
progression of the tumors. Mutant genes were found in tumors ranging from early 
stages of progression to very advanced stages of disease (Table 1). However, a 
striking difference was apparent between the position of the mutation at codon 12 
of the coK-ras gene and the degree of invasiveness of the tumors. While 4 of 9 
tumors mutant at the first position of codon 12 (NGT) were classified as being at 
an early stage of progression (Duke's O and A), 16 of the 18 tumors mutant at the 
second position of the triplet (GNT) were classifiéd as being more invasive 
(Duke's B, C, and D). Whether these differences are relevant in a clinical, 
prognostic context remains to be determined. 
Mutational Activation of coK-ras Genes in Colon Turnors at Early Stages 
of Progression 
Another interesting finding derived from our studies was the detection of 
mutant coK-ras oncogenes in premalignant villous adenomas. Villous adenomas or 
villoglandular polyps are relatively common types of benign solitary tumors which 
emerge directly from the colon mucosa as large superficial neoplasms most 
frequently in the rectum and rectosigmoid area. The incidence of malignant change 
of these types of benign turnors is higher than in adenomatous polyps. Villous 
adenomas frequently contain focal areas of malignant conversion to carcinoma 
cells, but are considered malignant only when infiltrating activity can be 
demonstrated by microscopic analysis (20). 
Of the eight colon turnors associated with villous adenomas that we have 
analyzed,seven contained mutations at codon 12 of the coK-ras gene, five in the 
first position, and two in the second (Table 1). The eight tumors analyzed were 
collected at different stages of progression. Tumors 3 and 28 were obtained at a 
very early stage of development. Turnor 3 was classified as a moderately 
differentiated adenocarcinoma arising within a villous adenoma, but the carcinoma 
119 
A 

a b e 
B 
FIGURE 4. Histopathological Analysis of Premalignant Human Primary Colon Tumors 
A) Histological photograph of villous adenoma 28. The features of a 
villoglandular polyp are demonstrated in an frozen section from the area adjacent 
to the tissue analyzed by the RNAse A mismatch cleavage method. Villi are 
apparent in panel c (x200) and complex glandular structures consistent with 
carcinoma in situ (CIS) can be seen between the black arrows in two areas of 
the polyp in frames a and b (x400 and x200, respectively). 
B) Histological photograph of tumor 3. The overall diagnosis was of an 
invasive adenocarcinoma ar1s1ng from a villoglandular polyp. The material 
remaining from the sample used for RNA and DNA preparation was prepared for 
frozen section. The section demonstrates villi in Frame a (x200). No invasive 
adenocarcinoma or carcinoma in situ is apparent (Frame b). 
120 
• • 
01 01 
"'"" "'"" 
:J: 
. "'"" Ul ...... 
¡,t') Tumor 28 1ºTransf. Z¡,t') 
10 1 ~a:: K-RAS:;; ' 1 2 	 3 4 5 6 7 8 9 Ulll. 
'+-6.7 
, 
.' 
N-RAS 
'
., 
--
. '~~.. +-3.0 
FIGURE 5. 	 Southern Blot Hybridization Analysis oi NIH3T3 Transformants Induced 
by DNA from Villous Adenoma 28. 
Ten micrograms of high molecular weight DNA from NIH3T3 primary 
transformants induced by DNA from villous adenoma 28 (lanes 1 through 10), from 
NIH3T3 cells (3T3), from a NIH3T3 primary transformant induced by DNA from the 
human neuroblastoma cell line SK-NS-H, and from a NIH3T3 primary transformant 
induced by DNA from the human lung carcinoma cell line PR37l, were digested with 
either EcoRl (K-ras) or PstI (N-ras) and electrophoresed through a 1% agarose 
gel. The D~A fragments were transferred to a nitrocellulose filter and hybridized 
to either 2P-labeled pKRSm2.6 K-ras specific probe or to pAN1Ngly N-ras specific 
probe. 
did not invade beyond the submucosal layer. Histopathological analysis of tumor 
28 revealed a villous adenoma with focal areas of non-invasive carcinoma in situ 
and was classified accordingly as a pre-malignant villous adenoma. 
Fragments of tumors 3 and 28 adjacent to the tissue used for RNA and DNA 
preparation were resubmitted for microscopic analysis. One of two fragments of 
tumor 28 contained carcinoma in situ (Figure 4A), while the other fragment from 
tumor28 and the fragment from tumor 3 (Figure 4B) contained only villous adenoma 
tissue. These results confirm the original classification of these tumors and 
indicate that mutant coK-ras genes were present in the premalignant adnomatous 
tissue. 
We also have analyzed six adenomatous polyps, only one of which scored 
positive in the RNAse A mismatch cleavage assay (Table 1 and K.F., C.A., M.P. in 
preparation). Interestingly, the polyp which was positive for a mutant coK-ras 
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gene by our assay was the only one that already containad carcinoma tissue. 
Although interpretation of these results will have to await further studies, a 
possibility is that while somatic ras mutational activation may be involved in 
the generation of premalignant villous adenomas, it may occur after of during the 
transition from adenoma to carcinoma in adenomatous polyps or tubular adenomas. 
Coexistence of coK-ras and N-ras Onco&enes in Villous Adenoma 28 
Our studies also revealed the simultaneous presence of both coK-ras and N­
ras activated oncogenes in human colon tumors (9). RNAse A mismatch cleavage 
analysis of tumor 28 revealed the presence of a mutant coK-ras oncogene in this 
villous adenoma which was confirmed by cloning and sequencing (Figure 3). 
However, parallel analysis of the transforming activity of tumor DNA by the 
NIH3T3 focus formation assay revealed the presence of a transforming gene in this 
tumor which was identified by Southern blot hybridization analysis of primary 
transformants as the N-ras oncogene. 
Repeated analysis by the NIH3T3 focus assay (Figure 5) with DNA prepared 
from different tumor fragments confirmed the simultaneous presence of N-ras and 
coK-ras oncogenes in villous adenoma 28. Thus, twelve out of sixteen total NIH3T3 
transformants contained N-ras sequences, while four contained coK-ras sequences 
(an example of these experiments is given in Figure 5). Although we cannot rule 
out the possibility that tumor 28 may have originated from two distinct cell 
populations, eaeh one containing a different mutated ras oncogene, we interpret 
this finding as indicative of the accumulation of mutations in ras genes during 
the process of tumor progression. Therefore, mutational activation of ras proto­
oncogenes may also occur at late stages of tumor development. 
In summary, our studies have revealed a relatively high incidence of mutant 
coK-ras oncogenes in human colon cancer supporting the concept that somatic ras 
mutational activation is playing an important role during the process of human 
tumor development and progression. In addition, the RNAse A mismatch cleavage 
method provides an alternative molecular diagnostic tool which could have 
prognostic application in human cancer. 
ACKNOWLEDGEMENTS 
We thank Concepcion Lama for her excellent ~echnical assistance and Kathy 
Sexton for help with the collection of tumor speeimens. This work was supported 
by NIH grant CA38579 awarded by the National Oancer Institute and by a grant 
from Toyo Jozo Ltd. Co. 
REFERENeES 
l. 	 Bisnop, J. M. The molecular genetics of cancer. Science 235: 305-311 (1987). 
2. 	 Lowy, p, R. and Willumsen,B M. The ras gene family. Cancer Surveys 5: 275­
289 (1987), 
3. 	 Barbacid, M, ras Genes. Ann. Rev. of Biochem.. 56: 779-827 (1987). 
4. 	 Kahn, S., Yamamoto, F., A1moguera, e., Winter, E., Forrester, K., Jordano, 
J., and Pe~~cho, M. The coK-ras gene and human cancer. Anticancer Research 
in press (¡987). 
5. 	 Winter, E •• Yamamoto. F., A1moguera, e., and Perycho, M. A method to detect 
and characterize point mutations in transcribed genes: Amp1ification and 
overexpression of the mutant c-Ki-ras a11e1e in human tumor cells. Prac. 
Nat1. Acad. Sci. USA 82: 7575-7579 (1985). 
6. 	 Graham, F. L. and van der Eb, A. J. A new technique for the assay of 
infectivity of human adenovirus 5 DNA. Viro1ogy 52: 456-467 (1973). 
122 
7. 	 Wigler, M., Pe11icer, A., Si1verstein, S., and Axe1, R. Transfer of single 
copy eukaryotic genes using total ce11ular DNA as donor. Cell 14: 725-731 
(1978). 
8. 	 Perucho, M., Goldfarb, M., Shimizu, K., Lama, C., Fogh, J., and Wigler. M. 
Human-tumor derived ce11 1ines contain common and different transforming 
genes. Ce11 27: 467-476 (1981). 
9. 	 Forrester, K.• A1moguera. C., Han, K., Grizz1e. W. E., and Perucho , M. 
Detection of high incidence of K-ras oncogenes during human colon 
tumorigenesis. Nature 327, 298-303 (1987). 
10. 	 Winter, E. and Perucho, M. Oncogene amplification during tumorigenesis of 
estab1ished rat fibrob1asts reversib1y transformed by activated human ras 
oncogenes. Mol. Ce11. Bio1. 6: 2562-2570 (1986). 
11. 	 Nakano, H., Yamamoto, F., Nevi11e, C., Evans. D., Mizuno, T., and Perucho, 
M. Isolation of transforming sequences of two 1ung carcinomas: Structura1 
and functiona1 analysis of the activated coK-ras oncogenes. Proc. Natl. 
Acad. Sci. USA 81: 71-75 (1984). 
12. 	 McCoy, M., Bargmann, C.J., and Weinberg, R.A. Human colon carcinoma Ki-ras 2 
oncogene and its corresponding proto-oncogene. Mol. Ce11. Bio1. 4: 1577-1582 
(1984). 
13. 	 Taparowsky, W., Shimizu, K., Go1dfarb, M., and Wig1er. M. Structure and 
activation of thehuman N-ras gene. Ce11 34: 581-586 (1983). 
14. 	 Me1ton, D. A., Krieg, P. A.• Rebag1iati, M. R., Maniatis, T., Zinn. K., and 
Green. M. R. Efficient in vitro synthesis of bio1ogica11y active RNA and 
bacteriophage RNA hybridization probes from a p1asmid containing a bacterio­
phage SP6 promoter. Nuc1. Acids. Res. 12: 7035-7056 (1984). 
15. 	 Maniatis. T.• Fritsch. E. F. and Sambrook, J. in Molecular C1oning. A Labor­
atory Manual. (Co1d Spring Harbor Laboratory, Co1d Spring Harbor, NY. 1982). 
16. 	 Myers, R. M., Larin. Z., and Maniatis, T. Detection of single base 
substitutions by ribonuc1ease c1eavage at mismatches in RNA:DNA dup1exes. 
Science 230: 1242-1246 (1985). 
17. 	 Capon. D. J .• Seeburg, P. H.• McGrath. J. P.• Hayf1ick. J. S., Edman, U.• 
Levinson. A. D., and Goedde1, D. V. Activation of Ki-ras-2 genes in human 
colon and 1ung carcinomas by two different point mutations. Nature 304: 
507-512 (1983). 
18. 	 Sugarbaker, P. H., Gunderson. L. L.• and Wittes. R. E. in Cancer Princip1es 
and Practice of Onco1ogy (eds. De Vita, V. T., He11man, S., and Rosenberg. 
S. A.) 814-816 (Lippineott, Phi1ade1phia. 1985). 
19. 	 Duesberg, P. H. Activated proto-one genes: Suffieient or neeessary for 
caneer? Seience 228: 669-677 (1985). 
20. 	 Ash1ey, D. J. B. in Histo1ogica1 Appearanees of Tumors 580-581 (Churehi11 
Livingstone, London, 1978). 
Address correspondence to: 
Dr. Manuel Perucho 
Department of Biochemistry 
State University of NewYork at Stony Brook 
Stony Brook. NY 11794-5215 USA 
123 
